SEB Bioteknikfond D vs UBS Lux Equity Fund Biotech USD

SEB Bioteknikfond D vs UBS Lux Equity Fund Biotech USD

1. SEB Bioteknikfond D

  • Security

    SEB Bioteknikfond D EUR Lux Utd

  • Fee

    1.69%

  • ISIN

    LU0118405827

  • Holdings

    24

2. UBS Lux Equity Fund Biotech USD

  • Security

    UBS Lux Equity Fund Biotech USD P-acc

  • Fee

    2.25%

  • ISIN

    LU0069152568

  • Holdings

    9

Fund Holdings

We have information about 24 holdings in SEB Bioteknikfond D, where the largest holding is Gilead Sciences (10.04), followed by Vertex (8.8) and Amgen (8.54). In comparison with UBS Lux Equity Fund Biotech USD, we have 11 holdings where Regeneron Pharmaceuticals is the largest holding (10.04), followed by Moderna (9.21) and Vertex (8.44).

All Holdings

Here we compare the holdings in SEB Bioteknikfond D and UBS Lux Equity Fund Biotech USD.

SEB Bioteknikfond D UBS Lux Equity Fund Biotech USD
1. Gilead Sciences Inc
USA
10.04 %
1. Regeneron Pharmaceuticals Inc
10.04 %
2. Vertex Pharmaceuticals Inc
8.8 %
2. Moderna Inc
9.21 %
3. Amgen Inc
USA
8.54 %
3. Vertex Pharmaceuticals Inc
8.44 %
4. Regeneron Pharmaceuticals Inc
5.09 %
4. Alnylam Pharmaceuticals Inc
8.08 %
5. Alnylam Pharmaceuticals Inc
5.07 %
5. AbbVie Inc
USA
4.91 %
6. AstraZeneca ADR
Sweden UK
4.49 %
6. Gilead Sciences Inc
USA
4.66 %
7. Verona Pharma ADR
3.46 %
7. Amgen Inc
USA
4.43 %
8. Argenx ADR
2.72 %
8. BioNTech SE
4.13 %
9. Illumina Inc
2.72 %
9. Karuna Therapeutics Inc
3.75 %
10. BioNTech SE
2.41 %
-
11. Madrigal Pharmaceuticals Inc
1.88 %
-
12. BoneSupport AB
Sweden
1.82 %
-
13. BioMarin Pharmaceutical Inc
1.7 %
-
14. Krystal Biotech Inc
1.48 %
-
15. NewAmsterdam Pharma NV
1.46 %
-
16. BridgeBio Pharma Inc
1.45 %
-
17. Cytokinetics Inc
1.4 %
-
18. Ionis Pharmaceuticals Inc
1.37 %
-
19. Xenon Pharmaceuticals
1.37 %
-
20. Insmed Inc
1.32 %
-
21. Onward Medical NV
1.31 %
-
22. Janux Therapeutics Inc
1.3 %
-
23. Structure Therapeutics ADR
1.24 %
-
24. Kymera Therapeutics Inc
1.09 %
-

The list of fund holdings was last updated on July 27, 2025.